

Susan Bressman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4077927/publications.pdf>

Version: 2024-02-01

33
papers

3,418
citations

361045

20
h-index

395343

33
g-index

33
all docs

33
docs citations

33
times ranked

5217
citing authors

#	ARTICLE	IF	CITATIONS
1	Deep Brain Stimulation of the Pallidofugal Pathways to Rescue Severe Life-Threatening Dyskinesias after STN-DBS Lead Implantation. <i>Stereotactic and Functional Neurosurgery</i> , 2022, 100, 95-98.	0.8	2
2	Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in <i>GBA</i> Mutation Carriers. <i>Annals of Neurology</i> , 2022, 91, 424-435.	2.8	46
3	Refractory Seizures Secondary to Vitamin B6 Deficiency in Parkinson Disease: The Role of Carbidopa-Levodopa. <i>Case Reports in Neurology</i> , 2022, 14, 291-295.	0.3	3
4	Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia. <i>Neuron</i> , 2021, 109, 1465-1478.e4.	3.8	21
5	Genomewide Association Studies of <i>LRRK2</i> Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 76-88.	2.8	30
6	Dysregulation of mitochondrial and proteolysosomal genes in Parkinson's disease myeloid cells. <i>Nature Aging</i> , 2021, 1, 850-863.	5.3	16
7	The minimal clinically important change in the motor section of the Burke-Fahn-Marsden Dystonia Rating Scale for generalized dystonia: Results from deep brain stimulation. <i>Parkinsonism and Related Disorders</i> , 2021, 93, 85-88.	1.1	3
8	Clinical and dopamine transporter imaging characteristics of non-manifest <i>LRRK2</i> and <i>GBA</i> mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , 2020, 19, 71-80.	4.9	94
9	Cervical Dystonia Incidence and Diagnostic Delay in a Multiethnic Population. <i>Movement Disorders</i> , 2020, 35, 450-456.	2.2	22
10	Nonsteroidal Anti-inflammatory Use and <i>LRRK2</i> Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020, 35, 1755-1764.	2.2	57
11	Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients. <i>Clinical Parkinsonism & Related Disorders</i> , 2020, 3, 100042.	0.5	4
12	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (<i>LRRK2</i>) and Glucosylceramidase Beta (<i>GBA</i>) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-sectional Study. <i>Movement Disorders</i> , 2020, 35, 833-844.	2.2	48
13	Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. <i>Movement Disorders</i> , 2019, 34, 1392-1398.	2.2	28
14	Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 531.	1.1	13
15	Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. <i>JAMA Neurology</i> , 2018, 75, 939.	4.5	256
16	Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn's disease and Parkinson's disease. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	273
17	High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. <i>Human Genetics</i> , 2018, 137, 343-355.	1.8	24
18	The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	1.7	330

#	ARTICLE	IF	CITATIONS
19	Increased substantia nigra echogenicity in <i>LRRK2</i> family members without mutations. <i>Movement Disorders</i> , 2018, 33, 1504-1505.	2.2	1
20	A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers. <i>Brain Structure and Function</i> , 2017, 222, 1207-1218.	1.2	22
21	Functional Genomic Analyses of Mendelian and Sporadic Disease Identify Impaired eIF2 \pm Signaling as a Generalizable Mechanism for Dystonia. <i>Neuron</i> , 2016, 92, 1238-1251.	3.8	68
22	Neuropsychiatric characteristics of GBA-associated Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2016, 370, 63-69.	0.3	50
23	Intact working memory in non-manifesting <i>LRRK2</i> carriers – an fMRI study. <i>European Journal of Neuroscience</i> , 2016, 43, 106-112.	1.2	16
24	Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2016, 28, 185-186.	0.8	33
25	Higher Frequency of Certain Cancers in <i>LRRK2</i> G2019S Mutation Carriers With Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 58.	4.5	76
26	Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 106-110.	1.1	58
27	Efficient estimation of nonparametric genetic risk function with censored data. <i>Biometrika</i> , 2015, 102, 515-532.	1.3	5
28	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. <i>Genetics in Medicine</i> , 2014, 16, 644-645.	1.1	7
29	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. <i>Nature Communications</i> , 2014, 5, 4835.	5.8	156
30	Parkinson disease phenotype in Ashkenazi jews with and without <i>LRRK2</i> G2019S mutations. <i>Movement Disorders</i> , 2013, 28, 1966-1971.	2.2	131
31	A Genome-Wide Scan of Ashkenazi Jewish Crohn's Disease Suggests Novel Susceptibility Loci. <i>PLoS Genetics</i> , 2012, 8, e1002559.	1.5	144
32	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology</i> , The, 2008, 7, 583-590.	4.9	1,340
33	Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. <i>Annals of Neurology</i> , 2000, 47, 369-373.	2.8	41